Document Detail


Prospective evaluation of quality of life and neurocognitive effects in patients with multiple brain metastases receiving whole-brain radiotherapy with or without thalidomide on Radiation Therapy Oncology Group (RTOG) trial 0118.
MedLine Citation:
PMID:  18164829     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
PURPOSE: Radiation Therapy Oncology Group (RTOG) 0118 randomized patients with multiple brain metastases to whole-brain radiotherapy (WBRT) +/- thalidomide. This secondary analysis of 156 patients examined neurocognitive and quality of life (QOL) outcomes. METHODS AND MATERIALS: Quality of life was determined with the Spitzer Quality of Life Index (SQLI). The Folstein Mini-Mental Status Exam (MMSE) assessed neurocognitive function. SQLI and MMSE were administered at baseline and at 2-month intervals. MMSE was scored with a threshold value associated with neurocognitive functioning (absolute cutoff level of 23) and with the use of corrections for age and educational level. RESULTS: Baseline SQLI predicted survival. Patients with SQLI of 7-10 vs. <7 had median survival time (MST) of 4.8 vs. 3.1 months, p = 0.05. Both arms showed steady neurocognitive declines, but SQLI scores remained stable. Higher levels of neurocognitive decline were observed with age and education-level corrections. Of patients considered baseline age/educational level neurocognitive failures, 32% died of intracranial progression. CONCLUSIONS: Quality of life and neuropsychological testing can be prospectively administered on a Phase III cooperative group trial. The MMSE should be evaluated with adjustments for age and educational level. Baseline SQLI is predictive of survival. Despite neurocognitive declines, QOL remained stable during treatment and follow-up. Poor neurocognitive function may predict clinical deterioration. Lack of an untreated control arm makes it difficult to determine the contribution of the respective interventions (i.e., WBRT, thalidomide) to neurocognitive decline. The RTOG has developed a trial to study the role of preventative strategies aimed at forestalling neurocognitive decline in this population.
Authors:
Benjamin W Corn; Jennifer Moughan; Jonathan P S Knisely; Sherry W Fox; Arnab Chakravarti; W K Alfred Yung; Walter J Curran; H Ian Robins; David G Brachman; Randal H Henderson; Minesh P Mehta; Benjamin Movsas
Related Documents :
18452499 - Swedish norms for word fluency tests: fas, animals and verbs.
11681549 - The differential impact of age on the phenomenology of melancholia.
15371099 - New norms for a new generation: cognitive performance in the framingham offspring cohort.
20865619 - Mental alternation test: administration mode, age, and practice effects.
9063339 - A 5-year longitudinal study of the mini-mental state examination in normal aging.
7794869 - The reproducibility of subjective appetite scores.
6730469 - Lack of association of diagonal earlobe crease with other cardiovascular risk factors.
23705009 - Intraguild interactions between egg parasitoids: window of opportunity and fitness cost...
17555229 - Potential effects of environmental contamination on yuma myotis demography and populati...
Publication Detail:
Type:  Journal Article; Multicenter Study; Randomized Controlled Trial     Date:  2007-12-31
Journal Detail:
Title:  International journal of radiation oncology, biology, physics     Volume:  71     ISSN:  0360-3016     ISO Abbreviation:  Int. J. Radiat. Oncol. Biol. Phys.     Publication Date:  2008 May 
Date Detail:
Created Date:  2008-04-14     Completed Date:  2008-06-09     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  7603616     Medline TA:  Int J Radiat Oncol Biol Phys     Country:  United States    
Other Details:
Languages:  eng     Pagination:  71-8     Citation Subset:  IM    
Affiliation:
Department of Radiation Oncology, Tel Aviv Medical Center, Tel Aviv, Israel. bencorn@tasmc.health.gov.il
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Age Factors
Aged
Aged, 80 and over
Antineoplastic Agents / therapeutic use
Brain Neoplasms / drug therapy,  radiotherapy*,  secondary*
Cognition / radiation effects*
Cognition Disorders / diagnosis,  etiology*
Cranial Irradiation / adverse effects*
Educational Status
Humans
Mental Status Schedule
Middle Aged
Neuropsychological Tests
Prospective Studies
Quality of Life*
Survival Analysis
Thalidomide / therapeutic use
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 50-35-1/Thalidomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessment of extended-field radiotherapy for stage IIIC endometrial cancer using three-dimensional ...
Next Document:  Vertebral body growth after craniospinal irradiation.